Recent corporate updates, clinical disclosures, and regulatory filings from Ocugen, Inc. focus on the ongoing advancement of its cutting-edge modifier gene therapy and vaccine development portfolios. Key milestones include clinical trial updates for its lead product candidates targeting inherited retinal diseases and geographic atrophy, alongside corporate announcements detailing successful cash runway extensions designed to fund operations through upcoming clinical readouts. Institutional reports also track regulatory designations and strategic partnerships intended to accelerate commercialization pathways.